Detection of prostate-specific membrane antigen positive lesions in patients with prostate cancer

Active Ingredient: Piflufolastat ¹⁸F

Indication for Piflufolastat ¹⁸F

Population group: men, only adults (18 years old or older)
Therapeutic intent: Diagnostic

Piflufolastat (18F) is for diagnostic use only.

Piflufolastat (18F) is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:

  • Primary staging of patients with high-risk PCa prior to initial curative therapy,
  • To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.

For this indication, competent medicine agencies globally authorize below treatments:

3-5 MBq/kg of body weight

For:

Dosage regimens

Intravenous, between 3 megabecquerel piflufolastat ¹⁸F per kilogram of body weight and 5 megabecquerel piflufolastat ¹⁸F per kilogram of body weight, one dose.

Detailed description

Piflufolastat is for use in designated nuclear medicine facilities only and should only be handled by authorised personnel.

The mean recommended activity of (18F) piflufolastat is 4 MBq/kg of body weight and can vary from 3 to 5 MBq/kg of body weight depending on the PET equipment and acquisition mode used. The minimum activity should not fall below 190 MBq and the maximum activity should not exceed 360 MBq.

Patient preparation

The patient should be well hydrated before the start of the examination and urged to void before the examination in order to reduce bladder activity and as often as possible during the first hours after the examination in order to reduce radiation exposure.

A diuretic expected to act within the uptake time period may be administered to improve interpretation of piflufolastat (18F) PET/CT as it results in less activity depositions in ureters and the bladder.

After the procedure

Close contact with infants and pregnant women should be restricted during the initial 12 hours following the injection.

Active ingredient

Piflufolastat ¹⁸F

Piflufolastat (18F) is a selective secondgeneration fluorine-18-labeled small-molecule PSMA inhibitor. Based on the intensity of the signals, PET images obtained using piflufolastat (18F) indicate the presence of PSMA expressing tissues.

Read more about Piflufolastat ¹⁸F

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.